Researchers at the University of South Australia (UniSA), including Dr. Nicole Dmochowska and Professor Benjamin Thierry, are developing a laparoscopic probe using quantum technology to enhance the detection and treatment of gastrointestinal cancers. Funded by the Federal Government’s Economic Accelerator Ignite Grant, the project partners with Ferronova to integrate iron-oxide nanoparticles (FerroTrace) for precise lymph node mapping during surgery.
This innovation aims to reduce invasive procedures and improve patient outcomes by enabling targeted cancer removal. Building on a successful phase-1 clinical trial for oral cancer, the probe is now being adapted for minimally invasive laparoscopic use. The technology offers a safer alternative to traditional methods, with potential applications in chemotherapy and radiotherapy patients. This advancement could significantly impact cancer treatment worldwide with an anticipated global market exceeding $2 billion annually.
New Quantum Technology Tool for Cancer Treatment
Researchers at the University of South Australia have developed a novel laparoscopic probe utilizing quantum technology to enhance cancer detection and treatment. This innovative tool aims to improve the precision of tumor mapping during surgery for gastrointestinal cancers, offering a minimally invasive approach.
The probe operates in conjunction with FerroTrace, an iron-oxide nanoparticle formulation by Ferronova, enabling accurate identification of cancerous lymph nodes. This method surpasses traditional techniques that often rely on radioactive tracers, particularly benefiting patients undergoing chemotherapy or radiotherapy before surgery.
A phase-1 clinical trial for oral cancer has already demonstrated the probe’s feasibility, with plans underway to miniaturize it for laparoscopic use. This advancement is expected to reduce surgical invasiveness and associated risks, such as infections and digestive issues.
Funded by the Federal Government’s AEA Ignite Grant, the project underscores Australia’s focus on medical science and quantum technology. The technology’s commercial potential is substantial, with an anticipated global market exceeding $2 billion annually, highlighting both its medical benefits and economic impact.
How the Quantum Probe Works with FerroTrace
The quantum probe developed by researchers at the University of South Australia leverages advanced quantum sensors to detect magnetic fields generated by FerroTrace, an iron-oxide nanoparticle formulation. FerroTrace accumulates in cancerous lymph nodes when injected into the body, creating a magnetic signature that the probe can precisely locate. This method provides a safer and more effective alternative to traditional radioactive tracers, reducing exposure to harmful radiation while improving detection accuracy.
The integration of quantum technology allows the probe to achieve unprecedented sensitivity, enabling surgeons to identify even small or deeply embedded tumours with high precision. Unlike conventional lymphatic mapping techniques, which may fail in patients undergoing chemotherapy or radiotherapy, the quantum probe’s magnetic detection mechanism remains reliable, ensuring accurate diagnosis and treatment planning.
Plans are underway to miniaturize the probe for laparoscopic surgery, a development that will further enhance its clinical utility by allowing less invasive procedures. This advancement is expected to reduce surgical risks such as infections and digestive complications while improving patient recovery times.
The Potential Impact on Cancer Treatment
The laparoscopic probe developed by researchers at the University of South Australia represents a significant advancement in cancer detection and treatment. By integrating quantum sensors, the probe achieves high sensitivity, enabling precise identification of magnetic fields generated by FerroTrace nanoparticles. This capability allows surgeons to locate even small or deeply embedded tumors with greater accuracy compared to traditional methods.
The use of FerroTrace eliminates the need for radioactive tracers, reducing patient exposure to harmful radiation while improving detection reliability. Unlike conventional lymphatic mapping techniques, which may fail in patients undergoing chemotherapy or radiotherapy, the quantum probe’s magnetic detection mechanism remains consistent, ensuring accurate diagnosis and treatment planning.
Funded by the Federal Government’s AEA Ignite Grant, the project aligns with Australia’s focus on advancing medical science and quantum technology. With an anticipated global market exceeding $2 billion annually, the probe not only offers significant medical benefits but also holds substantial economic potential. This dual impact highlights its role as a pivotal innovation in both healthcare and industry.
More information
External Link: Click Here For More
